Skip to main content
Infectious Diseases and Therapy logoLink to Infectious Diseases and Therapy
. 2024 Aug 13;13(9):2103. doi: 10.1007/s40121-024-01030-0

Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor

Takayuki Katsube 1,, Safwan Kezbor 2, Ryosuke Shimizu 1, Ryuji Kubota 1
PMCID: PMC11343925  PMID: 39136875

Correction to: Infect Dis Ther (2024) 13:597–607 10.1007/s40121-024-00946-x

In the original version of this article, legend of Fig. 1 was incorrect. The correct legend of Fig. 1 is given below. The original article has been corrected

Fig. 1 Mean (standard deviation) pharmacokinetic profiles of normal renal impairment participants and participants with renal impairment following single-dose administration of ensitrelvir 375 mg. Plasma concentrations of participants with normal renal impairment, open triangles; with mild renal impairment, filled circles; with moderate renal impairment, open circles; with severe renal impairment, filled triangles. The figures are in linear (upper) and semilogarithmic (lower) scales.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Infectious Diseases and Therapy are provided here courtesy of Springer

RESOURCES